A role of NKCC1 in the pathophysiology of these brain diseases is also evidenced by the beneficial effects observed with bumetanide (an NKCC1 inhibitor) administration (Lemonnier et al., 2016, 2017; Merner et al., 2016; Ben-Ari, 2017; Rahmanzadeh et al., 2017; Kharod et al., 2019; Mollajani et al., 2019; Zhang et al., 2020). This evidence concerns the gene SLC12A2 and brain disorder.